Introduction: Platelets play a role in the pathophysiology of venous thromboembolism (VTE). Some studies have not found an association between VTE and platelet aggregation. The PFA-100® analyser is an in vitro assay for assessing primary haemostasis. But, there are no studies to evaluate its association with VTE. We investigated the contribution of the global platelet function and aggregation in the development of VTE.

Material And Methods: We analysed 800 individuals who were included in the RETROVE Study (Riesgo de Enfermedad TROmboembólica VEnosa). Global platelet function was evaluated as closure times (CT) with the agonists ADP and epinephrine using a PFA-100® analyser. Platelet aggregation was evaluated by Multiplate™ analyser. The VTE risk for all the parameters was calculated by unconditional logistic regression analyses considering the potential confounders: age, gender, body mass index (BMI), factor VIII (FVIII), the von Willebrand factor (vWF) and the ABO blood group system.

Results: The unadjusted odds ratio (OR) values ≤10th percentile for the PFAadp and PFAepi were 4.02 (95% CI, 2.76-5.95) and 3.33 (2.27-4.97). Also, after adjusting for vWF, we obtained lower OR for the PFAadp and for PFAepi: 2.24 (1.44-3.49) and 1.63 (1.04-2.59). But, the whole blood aggregation parameters did not shown an association with VTE risk.

Conclusion: We demonstrated an association between short CT and VTE risk. Although, the whole blood aggregation parameters did not show an association with the VTE risk. This striking contrast suggests that there are other platelet function mechanisms (e.g. adhesion) that are responsible of VTE risk.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2018.07.012DOI Listing

Publication Analysis

Top Keywords

association vte
16
vte risk
16
platelet function
12
retrove study
8
vte
8
platelet aggregation
8
pfa-100® analyser
8
global platelet
8
pfaadp pfaepi
8
blood aggregation
8

Similar Publications

Development and validation of a nomogram for predicting venous thromboembolism risk in post-surgery patients with cervical cancer.

World J Surg Oncol

December 2024

Chongqing Cancer Multiomics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, 400030, China.

Objective: Postoperative venous thromboembolism (VTE) is a potentially life-threatening complication. This study aimed to develop a predictive model to identify independent risk factors and estimate the likelihood of VTE in patients undergoing surgery for cervical cancer.

Methods: We conducted a retrospective cohort study involving 1,174 patients who underwent surgery for cervical carcinoma between 2019 and 2022.

View Article and Find Full Text PDF

Background: The risk of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) in patients with psoriatic disease receiving biologics is not fully understood.

Objective: This study aimed to investigate whether novel biologic therapies (IL-17, IL-12/23, and IL-23 inhibitors) for biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) are associated with differences in the risks of MACE and VTE compared with those with TNF inhibitors.

Methods: An emulated target trial was designed by a nationwide cohort using data from the TriNetX Research Network.

View Article and Find Full Text PDF

Uncovering novel therapeutic clues for hypercoagulable active ulcerative colitis: novel findings from old data.

Gastroenterol Rep (Oxf)

December 2024

Department of Cardiovascular Surgery, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Shanwei, Guangdong, P. R. China.

Background: Hypercoagulability has been shown to act as an important component of ulcerative colitis (UC) pathogenesis and disease activity, and is strongly correlated with the occurrence of venous thromboembolism (VTE). This study aimed at providing novel therapeutic clues for hypercoagulable active UC.

Methods: The coagulation score model was developed using VTE cohorts, and the predictive performance of this model was evaluated by coagulation subtypes of UC patients, which were clustered by the unsupervised method.

View Article and Find Full Text PDF

Development and validation of machine learning models for predicting venous thromboembolism in colorectal cancer patients: A cohort study in China.

Int J Med Inform

December 2024

Chongqing Cancer Multiomics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing 400030, China. Electronic address:

Background: With advancements in healthcare, traditional VTE risk assessment tools are increasingly insufficient to meet the demands of high-quality care, underscoring the need for innovative and specialized assessment methods.

Objective: Owing to the remarkable success of machine learning in supervised learning and disease prediction, our objective is to develop a reliable and efficient model for assessing VTE risk by leveraging the fundamental data and clinical characteristics of colorectal cancer patients within our medical facility.

Methods: Six commonly used machine learning algorithms were utilized in our study to predict the occurrence of VTE in patients with rectal cancer.

View Article and Find Full Text PDF

Risk factors for venous thromboembolism in patients undergoing neoadjuvant chemotherapy as treatment for ovarian cancer.

Eur J Obstet Gynecol Reprod Biol

December 2024

Department of Gynaecological Oncology, West Kent Cancer Centre, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Maidstone, Kent ME16 9QQ, United Kingdom.

Objective: During the treatment of ovarian cancer, the risk of venous thromboembolism (VTE) post operatively is well established, however, patients may be at even greater risk during neoadjuvant chemotherapy (NACT). This study aimed to determine the incidence and timing of VTE amongst patients undergoing NACT, whether there was an association with survival, and examine risk factors associated with the development of VTE.

Study Design: This was a retrospective cohort study of patients diagnosed with ovarian, fallopian tube and primary peritoneal cancer receiving neoadjuvant chemotherapy betweenApril 2011 and April 2022 at a gynaecological cancer centre in England.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!